Pharmacokinetics of the Protease Inhibitor KNI-272 in Plasma and Cerebrospinal Fluid in Nonhuman Primates after Intravenous Dosing and in Human Immunodeficiency Virus-Infected Children after Intravenous and Oral Dosing
KNI-272 is a human immunodeficiency virus (HIV) protease inhibitor with potent activity in vitro. We studied the pharmacokinetics of KNI-272 in the plasma and cerebrospinal fluid (CSF) of a nonhuman primate model and after intravenous and oral administration to children with HIV infection. Plasma an...
Furkejuvvon:
| Publikašuvnnas: | Antimicrob Agents Chemother |
|---|---|
| Váldodahkkit: | , , , , , , , , , , |
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
American Society for Microbiology (ASM)
1998
|
| Fáttát: | |
| Liŋkkat: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC105689/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9661027/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.42.7.1815 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
